
THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:


1. Use of a pharmaceutically effective amount of a TLR7 modulating compound, or a pharmaceutically acceptable salt thereof, and an HIV antibody, in the preparation of a medicament for treating an HIV infection in a virologically suppressed human, wherein the TLR7 modulating compound is selected from a compound of Formula III, or a pharmaceutically acceptable salt thereof:



Formula III

wherein:

the D ring represents a moiety selected from:



and

wherein, in each instance, the pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl, or morpholinomethyl group is bound to the 3-position or 4-position of the phenyl ring to which it is bound;

L^1 is -O-; and

R^1 is unsubstituted C_1-C_6 alkyl.


2. The use of claim 1, wherein the HIV antibody is a broadly neutralizing HIV antibody.

3. The use of claim 2, wherein the broadly neutralizing HIV antibody is PGT121.

4. The use of claim 2, wherein the broadly neutralizing HIV antibody is 3BNC60.

5. The use of claim 2, wherein the broadly neutralizing HIV antibody is 3BNC117.


6. Use of a TLR7 modulating compound, or a pharmaceutically acceptable salt thereof, and an HIV antibody, in the preparation of a medicament for eliminating an HIV infection in a virologically suppressed human, wherein the TLR7 modulating compound is selected from a compound of Formula III, or a pharmaceutically acceptable salt thereof:





Formula III


wherein:

the D ring represents a moiety selected from:





,


,



and ,

wherein, in each instance, the pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl, or morpholinomethyl group is bound to the 3-position or 4-position of the phenyl ring to which it is bound;

L^1 is -O-; and

R^1 is unsubstituted C_1-C_6 alkyl.


7. Use of a TLR7 modulating compound, or a pharmaceutically acceptable salt thereof, an HIV antibody, and a latency-reversing agent, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating an HIV infection in a virologically suppressed human, wherein the TLR7 modulating compound is selected from a compound of Formula III, or a pharmaceutically acceptable salt thereof:



Formula III

wherein:

the D ring represents a moiety selected from:




and

wherein, in each instance, the pyrrolidin-1-ylmethyl, piperidin-1-ylmethyl, or morpholinomethyl group is bound to the 3-position or 4-position of the phenyl ring to which it is bound;

L^1 is -O-; and

R^1 is unsubstituted C_1-C_6 alkyl.


8. The use of any one of Claims 1 to 7, wherein the TLR7 modulating compound is selected from a compound of Formula IIIa, or a pharmaceutically acceptable salt thereof:



Formula III(a)


wherein the pyrrolidin-1-ylmethyl group is bound to the 3-position or 4-position of the phenyl ring.

9. The use of any one of Claims 1 to 7, wherein the TLR7 modulating compound is a compound of the formula:



or a pharmaceutically acceptable salt thereof.

10. The use of any one of Claims 1 to 7, wherein the TLR7 modulating compound is a compound of the formula:



or a pharmaceutically acceptable salt thereof.